Evidence map›Paper›PMID 38716731›Full record

ArticleJCI insight2024

MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infection.

Deborah L Cross, Erik D Layton, Krystle Kq Yu, Malisa T Smith, Melissa S Aguilar, Shamin Li, Elise C Wilcox, Aude G Chapuis, Harriet Mayanja-Kizza, Catherine M Stein and 5 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Advances in Single-Cell Sequencing for Infectious Diseases: Progress and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Recognition and control ofFrontiers in tuberculosis · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Deborah L CrossDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Erik D LaytonDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Krystle Kq YuDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Malisa T SmithDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Melissa S AguilarDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Shamin LiVaccine and Infectious Disease Division and.
Elise C WilcoxTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Aude G ChapuisTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Harriet Mayanja-KizzaDepartment of Medicine, Makerere University, Kampala, Uganda.
Catherine M SteinDepartment of Medicine and.
W Henry BoomDepartment of Medicine and.
Thomas R HawnDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Philip BradleyPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Evan W NewellVaccine and Infectious Disease Division and.
Chetan SeshadriDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

Funding

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)75N93019C00071 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI FORTUNE, SARAH · 2019 to 2025
$57.3M
Resistance to MTB infection in HIV infected individuals in Uganda and S. AfricaR01AI124348 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, HAWN, THOMAS R · 2016 to 2020
$11.3M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosisR01AI146072 · NIAID · UNIVERSITY OF WASHINGTON · PI CHETAN SESHADRI · 2020 to 2026
$6.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Qualification of Assays to Measure Human T-cell Responses Against Mycobacterial Lipid AntigensR01AI125189 · NIAID · UNIVERSITY OF WASHINGTON · PI SESHADRI, CHETAN · 2016 to 2020
$3.1M
Molecular modeling and machine learning for protein structures and interactionsR35GM141457 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2021 to 2025
$2.1M
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93019C00071NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS R01 AI124348NIAID NIH HHS R01 AI125189NIAID NIH HHS R01 AI146072NIDA NIH HHS 75N95020D00005NIGMS NIH HHS R35 GM141457ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

T cells are required for protective immunity against Mycobacterium tuberculosis. We recently described a cohort of Ugandan household contacts of tuberculosis cases who appear to "resist" M. tuberculosis infection (resisters; RSTRs) and showed that these individuals harbor IFN-γ-independent T cell responses to M. tuberculosis-specific peptide antigens. However, T cells also recognize nonprotein antigens via antigen-presenting systems that are independent of genetic background, known as donor-unrestricted T cells (DURTs). We used tetramer staining and flow cytometry to characterize the association between DURTs and "resistance" to M. tuberculosis infection. Peripheral blood frequencies of most DURT subsets were comparable between RSTRs and latently infected controls (LTBIs). However, we observed a 1.65-fold increase in frequency of MR1-restricted T (MR1T) cells among RSTRs in comparison with LTBIs. Single-cell RNA sequencing of 18,251 MR1T cells sorted from 8 donors revealed 5,150 clonotypes that expressed a common transcriptional program, the majority of which were private. Sequencing of the T cell receptor α/T cell receptor δ (TCRα/δ) repertoire revealed several DURT clonotypes were expanded among RSTRs, including 2 MR1T clonotypes that recognized mycobacteria-infected cells in a TCR-dependent manner. Overall, our data reveal unexpected donor-specific diversity in the TCR repertoire of human MR1T cells as well as associations between mycobacteria-reactive MR1T clonotypes and resistance to M. tuberculosis infection.

Indexed as

Mycobacterium tuberculosisAdultClone CellsDisease ResistanceFemaleHistocompatibility Antigens Class IHumansLatent TuberculosisMaleMinor Histocompatibility AntigensT-LymphocytesTuberculosisUgandaYoung AdultHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanImmunologyInfectious diseaseT cell receptorT cells

Identifiers

PMID38716731
PMCPMC11141901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.